Halozyme Therapeutics (NASDAQ:HALO) CEO Helen Torley Sells 20,000 Shares of Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) CEO Helen Torley sold 20,000 shares of the stock in a transaction dated Friday, September 11th. The shares were sold at an average price of $107.24, for a total value of $2,144,800.00. Following the completion of the transaction, the chief executive officer owned 767,780 shares in the company, valued at approximately $82,336,727.20. The trade was a 2.54% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Helen Torley also recently made the following trade(s):

• On Wednesday, September 9th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $107.43, for a total value of $2,148,600.00.
• On Tuesday, August 18th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $104.18, for a total value of $2,083,600.00.
• On Wednesday, July 8th, Helen Torley sold 1,923 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $79.77, for a total transaction of $153,397.71.

Halozyme Therapeutics Stock Up 0.2%

HALO stock opened at $107.20 on Friday. The company has a current ratio of 2.71, a quick ratio of 2.31 and a debt-to-equity ratio of 13.50. Halozyme Therapeutics, Inc. has a twelve month low of $61.22 and a twelve month high of $111.15. The company’s 50 day moving average is $93.73 and its two-hundred day moving average is $76.97. The stock has a market cap of $12.17 billion, a P/E ratio of 32.00, a PEG ratio of 0.41 and a beta of 0.88.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.79 by $0.49. The business had revenue of $481.00 million during the quarter, compared to analysts’ expectations of $402.28 million. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The company’s revenue for the quarter was up 47.7% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.54 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Research analysts expect that Halozyme Therapeutics, Inc. will post 8.25 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Halozyme Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Measured Wealth Private Client Group LLC grew its stake in shares of Halozyme Therapeutics by 51.5% during the 4th quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 124 shares during the period. Larson Financial Group LLC increased its holdings in shares of Halozyme Therapeutics by 3,118.2% in the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 343 shares in the last quarter. MidFirst Bank acquired a new stake in shares of Halozyme Therapeutics in the second quarter valued at about $27,000. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in Halozyme Therapeutics during the second quarter worth about $28,000. Finally, Quantbot Technologies LP purchased a new stake in Halozyme Therapeutics during the second quarter worth about $30,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Leerink Partners upgraded Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and lifted their target price for the stock from $83.00 to $110.00 in a research report on Friday, August 7th. Weiss Ratings raised Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research report on Monday, August 31st. Citigroup restated a “market outperform” rating on shares of Halozyme Therapeutics in a research note on Friday, August 7th. TD Cowen boosted their price objective on Halozyme Therapeutics from $96.00 to $105.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Finally, HC Wainwright reissued a “buy” rating and issued a $115.00 price objective on shares of Halozyme Therapeutics in a report on Wednesday, September 2nd. Nine equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $91.20.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of medicines. The company’s primary technology is ENHANZE, which uses recombinant human hyaluronidase PH20 to facilitate the subcutaneous delivery of certain biologic and other injectable therapies that might otherwise require intravenous infusion.

Halozyme provides ENHANZE technology to pharmaceutical and biotechnology partners through licensing and collaboration agreements.